ABSTRACT
The effectiveness and safety of treatment with vobenzyme supplemented to the standard antibiotic therapy have been compared in 60 patients. Addition of vobenzyme to the standard antibiotic therapy significantly reduces the number and degree of respiratory symptoms has a pronounced effect on the activity of inflammation, leads to a more complete reversal of pulmonary parenchymatous infiltration on a roentgenogram, contributes to the achievement of the maximum efficiency of treatment, and substantially diminishes residual respiratory symptoms of pneumonia economically expediently and safety at a late follow-up.
Subject(s)
Community-Acquired Infections/drug therapy , Enzyme Therapy , Pneumonia, Bacterial/drug therapy , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/diagnostic imaging , Dose-Response Relationship, Drug , Drug Therapy, Combination , Enzymes/administration & dosage , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pneumonia, Bacterial/diagnostic imaging , Radiography, Thoracic , Treatment Outcome , Young AdultSubject(s)
Occupational Diseases/epidemiology , Occupations , Respiratory Tract Diseases/epidemiology , Adult , Aged , Cough/epidemiology , Female , Humans , Immunoglobulin E/immunology , Male , Middle Aged , Occupational Diseases/immunology , Occupations/statistics & numerical data , Respiratory Tract Diseases/immunologyABSTRACT
AIM: To study clinical efficiency of 12-month administration of berodual in chronic obstructive bronchitis (COB). MATERIALS AND METHODS: The trial entered 33 patients with at least 2-year history of COB and forced expiratory volume per 1 sec (FEV1) not less than 45% of normal value. RESULTS: The best response of clinical parameters and external respiration was observed throughout 3 weeks of berodual inhalations. Dyspnea and cough were cured by the end of the treatment in 40 and 26% of the patients, respectively. Exercise tolerance has improved, FEV1 has increased for the year from 71.9 to 79.1%. CONCLUSION: Long-term berodual monotherapy is able to inhibit progression of bronchial obstruction and symptoms of COB.